2023
Circulating Levels of Leptin and Lipocalin-2 in Patients With X-Linked Hypophosphatemia
Simpson C, Santoro A, Carpenter T, Deng Y, Parziale S, Insogna K. Circulating Levels of Leptin and Lipocalin-2 in Patients With X-Linked Hypophosphatemia. Journal Of The Endocrine Society 2023, 7: bvad116. PMID: 37860221, PMCID: PMC10583534, DOI: 10.1210/jendso/bvad116.Peer-Reviewed Original ResearchLipocalin-2Control subjectsGreater riskLevels of LCN2Excessive weight gainLevels of leptinSerum leptin levelsCirculating LevelsLCN2 levelsSerum levelsYear age cohortLeptin levelsMetabolic abnormalitiesRetrospective studyAge cohortsInsulin sensitivityHigh prevalencePatientsWeight gainXLHLeptinAge 2HypophosphatemiaObesityChildren
2021
Serum Levels of Lipocalin Are Lower in Adolescents With X-Linked Hypophosphatemia
Simpson C, Santoro A, Carpenter T, Insogna K. Serum Levels of Lipocalin Are Lower in Adolescents With X-Linked Hypophosphatemia. Journal Of The Endocrine Society 2021, 5: a27-a27. PMCID: PMC8089365, DOI: 10.1210/jendso/bvab048.052.Peer-Reviewed Original ResearchWeight/height z-scoreHeight z-scoreExcessive weight gainZ-scoreFibroblast growth factor 23Greater riskWeight gainRegular aerobic exerciseDirect pathogenic roleGrowth factor 23Impaired glucose metabolismVitamin D testingElderly normal individualsAbility of patientsAccelerated osteoarthritisAdult patientsPediatric patientsSerum levelsFactor 23Metabolic abnormalitiesAbnormal biomechanicsInsulin levelsAerobic exerciseInsulin sensitivityPathogenic role
2009
The Effect of Proton Pump-Inhibiting Drugs on Mineral Metabolism
Insogna KL. The Effect of Proton Pump-Inhibiting Drugs on Mineral Metabolism. The American Journal Of Gastroenterology 2009, 104: ajg200944. PMID: 19262542, DOI: 10.1038/ajg.2009.44.BooksConceptsProton pump inhibitorsMineral metabolismLong-term proton pump inhibitorsIntestinal calcium absorptionHip fracture ratesClass of drugsFragility fracturesBone lossCalcium economyPump inhibitorsCalcium absorptionFracture ratesCalcium balanceSkeletal homeostasisGreater riskAdverse effectsHigh rateDrugsRecent studiesMetabolismLong term
2008
Proton pump-inhibiting drugs, calcium homeostasis, and bone health
Wright MJ, Proctor DD, Insogna KL, Kerstetter JE. Proton pump-inhibiting drugs, calcium homeostasis, and bone health. Nutrition Reviews 2008, 66: 103-108. PMID: 18254877, DOI: 10.1111/j.1753-4887.2008.00015.x.Books
2007
The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism
Nakchbandi IA, Lang R, Kinder B, Insogna KL. The Role of the Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Cytokine System in Primary Hyperparathyroidism. The Journal Of Clinical Endocrinology & Metabolism 2007, 93: 967-973. PMID: 18073309, PMCID: PMC2266956, DOI: 10.1210/jc.2007-1645.Peer-Reviewed Original ResearchConceptsNuclear factor-kappaB ligandPrimary hyperparathyroidismBone lossReceptor activatorTotal femurIL-6Bone resorptionIL-6 soluble receptorMild primary hyperparathyroidismBone mineral densitySoluble receptor activatorMechanism of actionIL-6sRSRANKL levelsSerum levelsBone turnoverMineral densityCytokine systemSoluble receptorHyperparathyroidismNormal rangeSkeletal responsivenessBiochemical markersPatientsGreater risk